GTM Audit or Expensive Slideware? Why Smart Founders Test Before They Scale Outbound

Microsoft has some of the best product minds on earth. Yet when its teams tested their own ideas properly, about two-thirds of the changes had no effect or made things worse.

That finding comes from Ron Kohavi and colleagues, who ran experiments at Microsoft and Bing for years. It's summed up in the Harvard Data Science Review. At Google and Bing, only 10% to 20% of changes improved the number they were meant to move.

Now think about the message your firm plans to send to a thousand strangers next quarter. It's an idea too. Nobody has tested it.

Here's why that matters to you. When a services founder hears "diagnostic," they hear "consultants charging me to tell me what I already know." Many have paid for exactly that. A thick PDF. A nice readout. Nothing changed.

So when a firm like mine says the first step is an $11,500 GTM Viability Sprint, the reaction is fair. I don't want to pay $11,500 for a deck.

Neither would I. Below, I'll show you how to tell real research from slideware, what skipping diagnosis actually costs, and why the most valuable answer a diagnostic can give you is sometimes "no."

But first, the question underneath all of this. If even Microsoft's experts are wrong two times out of three, what are the odds your untested message is right, and how would you ever know before you've spent the money?

"I don't want to pay $11,500 for a deck." Fair enough.

Because you've probably seen what a deck is worth. Nothing, the day after the readout.

Picture Maria. She runs a $9M data consultancy in Chicago. Referrals built the firm. Lately they've thinned out, and her partners want a plan.

She has two proposals on her desk. One is an outbound agency: about $6,000 a month, starting next week, with a promise of meetings. The other is a $11,500 diagnostic that takes six to eight weeks before anything gets "built."

Her gut picks the agency. It feels like action. The diagnostic feels like paying for homework.

That instinct isn't foolish. Maria is busy. Her partners are impatient. And she already knows her clients better than any outsider could. Why pay someone to learn what she knows?

It's the same reasoning that sends many services founders straight to their first agency. When we researched US services firms, we found many of them retreat to referrals after that agency burns them, poorer and more skeptical.

Still, Maria's fear has a real basis. Most diagnostics really are slideware. So how would she tell the difference?

What's true: most GTM audits are slideware

Let me say this plainly. A lot of what gets sold as a "GTM audit" is a sales funnel with a PDF on top.

You've seen the pattern. An agency offers a cheap or free "assessment." Two weeks later you get a deck full of frameworks, and every slide points to the same conclusion: you need the agency's main service. The audit wasn't built to find the truth. It was built to find a yes.

Here's the simplest test I know. If every diagnostic a firm runs ends in "buy the big thing," it was never a diagnostic. It was a demo.

Slideware has other tells too:

• Opinions, not evidence. "Your ICP should be mid-market fintech" with nothing behind it but the consultant's hunch.
• No contact with the market. Nobody spoke to a buyer or tested a message. It's all desk work.
• No decision at the end. Lots of "recommendations," no clear verdict.
• Nothing you can reuse. Once the meeting ends, the deck sits in a folder.

If Maria has bought one of those before, her skepticism is earned.

Unsure how your own firm looks to a cold buyer right now? The 2-minute Pipeline Engine Diagnostic gives you a quick score, free.

But slideware existing doesn't mean the real thing isn't needed. Maria still believes she knows her buyer. Does she?

Why your outbound message is a guess, even if you know your clients well

Because knowing your clients and knowing your next buyer are two different things.

Services firms grow in a particular way. You win work through people who trust you. Over ten years you collect 20 to 60 clients, from 20 to 60 different doors. Each one came for its own reason. Look at that list and you see a portfolio. You don't see a pattern.

Then you write an outbound message based on that portfolio. It sounds right to you because you wrote it. That feeling is the problem.

The inside view

In a well-known Harvard Business Review article, Dan Lovallo and Nobel winner Daniel Kahneman explained why smart leaders keep over-promising on new projects. They take the "inside view." They focus on the details of their own plan and overlook how similar plans usually turn out.

Their fix was to look outward. Before trusting your plan, check what happened to plans like it.

For outbound, the outside view is sobering. Plans like Maria's usually fail. Not because the firm is weak, but because the message was never tested against the people it's meant for.

Experts can't pick winners either

The experiment research makes the same point from another angle. In Harvard Business Review, Ron Kohavi and Stefan Thomke describe a Bing headline change that nobody rated as important. When someone finally tested it, it lifted revenue by 12%, worth more than $100 million a year in the US alone.

Experts didn't see it coming. Nobody can reliably guess which message will work. You can only test.

That's what a real diagnostic is for. So what does one actually look like?

What a real GTM audit actually does

It does three things slideware never does. It talks to the market, it tests, and it decides.

I learned the value of the first step early. At Frost & Sullivan, where I sold the biggest consulting workshop the company had run, the lesson was clear: senior buyers pay for depth of thinking. They pay for research they can act on, and they ignore the rest.

What changes when the foundation comes first

One of the clearest examples I've seen was a 260-person Microsoft Partner in Kochi. This was work I led before ProspectWise took its current shape. The firm kept clients for years. It simply couldn't win new ones on a steady basis. Its outreach led with capabilities: what they could do, not what buyers needed.

We didn't start by sending more. We started by rebuilding the offer, moving from capability pitching to a few sharp offers tied to specific buyers. Only then did we switch on the outreach, using the team they already had.

The result was $1.8 million in qualified pipeline and 42 qualified meetings. Same people. Different foundation.

If you'd like to see what inspectable research looks like, here's a complete sample teardown for a fictional firm. It's a thin slice of what a full diagnostic produces.

So the research is real. But is it worth $11,500 of Maria's money?

The math: what skipping diagnosis really costs

Skipping a diagnostic doesn't save money. It just moves the cost to later, and makes it bigger.

Look at what Maria is comparing. One agency's own 2026 pricing guide puts mid-market multichannel retainers at $5,000 to $9,000 a month. Give an agency one quarter to prove itself, and that's $15,000 to $27,000.

The Bridge Group's data comes mostly from SaaS companies, so treat it as a floor for services firms, not a ceiling. Either way, the untested paths cost more, and teach less.

There's also the cost that never shows on an invoice: time. The Hinge Research Institute's 2026 High Growth Study of 770 professional services firms found median growth has slowed to 9.9%, the lowest since 2018. In a slower market, a lost quarter hurts more.

And when deals do die, the reasons point straight back to foundation work. In HubSpot's 2025 State of Sales report, a survey of 1,000 sales professionals, the top two deal killers were poor fit (37%) and weak perceived value (35%). Both are fixed before outreach, not during it.

So the numbers favor testing first. But there's one outcome that still scares founders. What if Maria pays, and the answer is "not yet"?

What if the diagnostic says "not yet"?

Then it did its job.

About a third of our Sprints end in "Not Yet." That's not a failure rate. That's the point. A diagnostic that can't say no can't protect you.

Buyers already understand this in other parts of their business. Forrester's State of Business Buying 2026 found more than 60% of business buyers now pay for some form of trial before a full purchase. Only just over a third planned to convert with the same provider. Trials exist so you can learn cheaply and walk away if needed. Nobody calls that wasted money.

A "Not Yet" verdict works the same way. Here's what you still walk away with:

• Four research documents you keep: your buyer research, a competitor and alternatives brief, your message architecture, and a map of how your buyers move from first interest to signing.
• A ranked fix list you can work through with your own team.
• A year you didn't waste pushing outreach into a market that wasn't ready.

The alternative is finding the same answer months and tens of thousands of dollars later, with a burned domain and a team that no longer believes outbound works.

Good. So how does Maria make sure she's buying the real thing and not a prettier deck?

The slideware test: 7 questions to ask before you pay for any diagnostic

Use these on anyone, including us.

1. Will you talk to or test against real buyers in my market, or is this desk research?
2. What will I have in my hands at the end that I can reuse without you?
3. Do you agree success thresholds in writing before any test runs?
4. How often do your diagnostics end in "don't buy the next stage"? If the answer is "never," walk away.
5. Is the next stage sold only after a positive verdict, or can I buy it anyway?
6. Who does the research, and have they done it for services firms like mine?
7. Does any of the fee credit toward what comes next?

Question 4 matters most. It separates a diagnostic from a demo in one answer.

Fair questions. So how would we answer them?

How the ProspectWise Sprint works

ProspectWise is a Bengaluru-based GTM firm for founder-led B2B tech services and consulting firms. Our GTM Viability Sprint is built to pass the test above.

• Weeks 1 to 3: find what's true. Deep buyer research using your buyers' own words, a competitor and alternatives brief, a message architecture, and a buyer journey map.
• Weeks 3 to 5: test it live. Two or three buyer-and-message hypotheses, thresholds agreed with you in writing, then small campaigns: cold email from our own pre-warmed setup, LinkedIn outreach, and one paid test.
• Week 6: the verdict. Build, Iterate or Not Yet, with the data attached.
• The terms: $11,500 fixed. $3,500 credits toward the Engine Build. We only sell the build after a Build verdict. Never on its own.

The limits, honestly: some markets give a clear reading in four weeks, others need a second round of tests. The Sprint ends when the reading is clear, either way. And we're small, so we run only a few at a time.

If you'd like to pressure-test whether your firm needs this at all, book a strategy call with me. Sometimes the honest answer is that you don't.

Which brings us back to Maria, and those two proposals. What did she choose?

Frequently asked questions

What is a GTM audit?

A GTM audit checks whether your go-to-market plan will work before you scale it: who your best buyers are, what message moves them, which channels reach them, and whether the evidence supports investing now. A real audit tests ideas against the live market. A weak one only reviews your materials and offers opinions.

How much does a GTM audit or diagnostic cost?

It varies widely, from free agency "assessments" to five-figure paid studies. Free ones are usually sales tools. Paid ones are worth it when they include live market testing and a clear verdict. Our GTM Viability Sprint is a fixed $11,500 for six to eight weeks, with $3,500 credited toward a build.

We already know our ICP. Do we still need a diagnostic?

Maybe not, and a good diagnostic will confirm that fast. But in many services firms, the clients you describe and the clients who actually pay well are different groups. Referral-built firms often serve dozens of unrelated clients. Testing your stated ICP against the live market is cheap insurance before bigger spending.

How long does a GTM diagnostic take?

A real one takes four to eight weeks, because live tests need time to produce signal. Anything much faster is usually desk research only. Our Sprint runs six to eight weeks: about three weeks of research, two to three weeks of live testing, then a written verdict.

What happens if the diagnostic says "not yet"?

You keep the research, get a ranked fix list, and avoid spending on outreach that the market isn't ready for. About a third of our Sprints end this way. We don't take build money after a "Not Yet." You can fix the gaps with your own team and come back when the foundation is ready.

What Maria did

Picture how this plays out.

Maria doesn't pick either proposal straight away. She sends both firms the same question: How often do your diagnostics tell a client not to buy the next stage?

The agency says it doesn't run diagnostics, it runs campaigns. Fair enough. The research firm says about a third of the time, and sends a sample of the work.

Now she's not choosing between action and homework. She's choosing between testing her idea and betting on it.

Remember Microsoft. Two out of three good ideas didn't work. The teams that won weren't the ones with better guesses. They were the ones who tested before they scaled.

Test the message before you pay to shout it.